{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T02:37:43Z","timestamp":1776566263110,"version":"3.51.2"},"reference-count":6,"publisher":"BMJ","issue":"6471","license":[{"start":{"date-parts":[[1985,3,16]],"date-time":"1985-03-16T00:00:00Z","timestamp":479779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br Med J (Clin Res Ed)"],"published-print":{"date-parts":[[1985,3,16]]},"abstract":"<jats:p>To assess the effect of cimetidine and ranitidine on high density lipoprotein (HDL) cholesterol concentration two groups of eight patients with duodenal ulcer or oesophagitis matched for age, sex, and cigarette consumption were given either cimetidine 1 g daily or ranitidine 300 mg daily for one month. There was no significant change in the cholesterol content of HDL and its subfraction HDL3 after treatment with ranitidine or cimetidine, or in the cholesterol content of the subfraction HDL2 after treatment with ranitidine; the HDL2 cholesterol concentration was, however, significantly increased after treatment with cimetidine. Further studies are being undertaken to establish the mechanism of this effect.<\/jats:p>","DOI":"10.1136\/bmj.290.6471.807","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T11:00:59Z","timestamp":1238670059000},"page":"807-808","source":"Crossref","is-referenced-by-count":5,"title":["Effects of cimetidine and ranitidine on high density lipoprotein cholesterol concentrations."],"prefix":"10.1136","volume":"290","author":[{"given":"J A","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I F","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1985,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(83)92217-1","article-title":"Cimetidine and HDL cholesterol","volume":"i:","author":"Miller, N.E.; Lewis, B.","year":"1983","unstructured":"Miller NE, Lewis B. Cimetidine and HDL cholesterol. Lancet 1983;i:529.","journal-title":"Lancet"},{"key":"ref_2","first-page":"152","article-title":"The effects of cimetidine on serum and lipoprotein lipids in normal subjects","volume":"15","author":"true","year":"1983","unstructured":"Bolton CH, Daneshmend TK, Ene MD, et al. The effects of cimetidine on serum and lipoprotein lipids in normal subjects. Br J Clin Pharmacol 1983;15:152.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0022-2275(20)38059-7","article-title":"Separation and quantitation of subclasses of human plasma HDL by a simple precipitation procedure","volume":"23","author":"Gidez, L.I.; Miller, G.J.; Burstein, M.","year":"1982","unstructured":"Gidez LI, Miller GJ, Burstein M, et al. Separation and quantitation of subclasses of human plasma HDL by a simple precipitation procedure. J Lipid Res 1982;23:1206.","journal-title":"J Lipid Res"},{"key":"ref_4","first-page":"215","article-title":"Effects of androgens and oestrogens on serum lipids and the composition of serum lipoproteins in normolipaemia and hyperlipaemic states","volume":"2","author":"Furman, R.H.; Alaupovic, P.J.; Howard, R.P.","year":"1967","unstructured":"Furman RH, Alaupovic PJ, Howard RP. Effects of androgens and oestrogens on serum lipids and the composition of serum lipoproteins in normolipaemia and hyperlipaemic states. Prog Biochem Pharmacol 1967;2:215-49.","journal-title":"Prog Biochem Pharmacol"},{"key":"ref_5","article-title":"Accepted","year":"1984","unstructured":"(Accepted 13 December 1984)"},{"key":"ref_6","article-title":"A human retrovirus-human T cell lymphotropic virusIII (HTLV-III)-has recently emerged as the probable cause of acquired immunodeficiency syndrome (AIDS). In May 1984, 250 outpatients at a hospital in a remote area of eastern Zaire were surveyed for AIDS type illnesses and the prevalence of antibodies against HTLV-III determined by an enzyme linked immunosorbent assay using disrupted whole HTLV-III virus as the antigen. No clinical cases of AIDS were diagnosed among these patients","unstructured":"A human retrovirus-human T cell lymphotropic virusIII (HTLV-III)-has recently emerged as the probable cause of acquired immunodeficiency syndrome (AIDS). In May 1984, 250 outpatients at a hospital in a remote area of eastern Zaire were surveyed for AIDS type illnesses and the prevalence of antibodies against HTLV-III determined by an enzyme linked immunosorbent assay using disrupted whole HTLV-III virus as the antigen. No clinical cases of AIDS were diagnosed among these patients."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.290.6471.807","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.290.6471.807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:32:47Z","timestamp":1765549967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.290.6471.807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,3,16]]},"references-count":6,"journal-issue":{"issue":"6471","published-online":{"date-parts":[[1985,3,16]]},"published-print":{"date-parts":[[1985,3,16]]}},"alternative-id":["10.1136\/bmj.290.6471.807"],"URL":"https:\/\/doi.org\/10.1136\/bmj.290.6471.807","relation":{},"ISSN":["0267-0623","1468-5833"],"issn-type":[{"value":"0267-0623","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,3,16]]}}}